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Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive 
fibrosis and a poor prognosis. Alveolar epithelial cells (AECs) are considered to play 
important roles by releasing growth factors and matrix metalloproteinases (MMPs), and 
by being involved in epithelial mesenchymal transition in IPF. Doxycycline 
hydrochloride (DOXY), an inhibitor of MMPs, attenuates pulmonary fibrosis in models 
and in patients with IPF; however, the mechanism of this action remains obscure. 
Objectives: The present study investigated the effect of DOXY upon growth factors and 
MMP production in AECs. Methods: Bleomycin (BL)-induced murine pulmonary 
fibrosis was treated with DOXY, and examined by pathological and 
immunohistochemical staining. The human alveolar epithelial cell line A549 was 
stimulated with transforming growth factor (TGF)-β1 and incubated with DOXY, and 
then the expression of growth factors, MMPs and collagen type I was evaluated at the 
mRNA and protein levels. We also evaluated the effects of DOXY on the 
TGF-β1-induced Smad signaling pathway. Results: DOXY reduced fibrosis scores and 
the production of collagen type I, connective tissue growth factor (CTGF) and TGF-β1 
in BL models. DOXY inhibited the mRNA expression of MMP-2, -9, CTGF and 




factor-AA protein induced in A549 cells by TGF-β1, but not by Smad2 and Smad3 
phosphorylation. We did not find a similar effect of DOXY in normal lung fibroblasts. 
Conclusions: Our results suggested that DOXY could be useful for attenuating 






Idiopathic pulmonary fibrosis (IPF) is the most common progressive and lethal 
pulmonary fibrotic disorder, but its etiology is unknown. The pathogenesis of IPF was 
originally thought to involve lung damage of unknown origin that produced an 
inflammatory response leading to fibrosis. However, recent findings suggest that 
epithelial cell damage is the initial event that triggers a series of repair pathways that are 
in some way aberrant and lead to inappropriate fibrosis [1]. During this process of 
pulmonary fibrosis, epithelial damage causes the consecutive release of several fibrotic 
mediators including growth factors such as transforming growth factor (TGF)-β, platelet 
derived-growth factor (PDGF), connective tissue growth factor (CTGF) and hepatocyte 
growth factor (HGF), as well as metalloproteinases (MMPs). These mediators provoke 
the migration, proliferation, and activation of mesenchymal cells with the formation of 
active fibroblastic/myofibroblastic foci, leading to the exaggerated accumulation of 
extracellular matrix (ECM) that mirrors abnormal wound repair [2]. Alveolar epithelial 
cells (AECs) apparently serve as progenitor cells that can undergo differentiation to 
fibroblasts/myofibroblasts in the presence of TGF-β [3,4]. This process is called 
epithelial mesenchymal transition (EMT) and could regulate pulmonary fibrosis. 




protein synthesis and exerts anti-inflammatory effects as well as apoptosis [5] [6] [7]. 
DOXY also inhibits MMPs and thus has been widely applied to treat aneurysms [8], 
periodontal disease [9], cancer, bone metastasis [10] and pleurodesis. The mechanisms 
of MMP inhibition by DOXY are not yet completely understood, but DOXY binds 
directly to the active target site of MMPs and induces degradation of the pro-MMP 
zymogen or provokes the inhibition of MMP mRNA transcription [11]. In the 
bleomycin (BL)-induced model of pulmonary fibrosis, DOXY attenuates fibrosis 
through MMP inhibition [12], which led to the notion that preventing MMP activity 
could be of therapeutic benefit to patients with IPF. The results of a recent small open 
trial of such patients indicate that long-term DOXY administration might be a candidate 
therapeutic regimen [13]. However, the definitive mechanism of DOXY with respect to 
pulmonary fibrosis and its specific effects on alveolar epithelial cells in pulmonary 
fibrosis remain obscure. 
We evaluated the effect of DOXY on the BL-induced pulmonary fibrosis model in 
vivo, and on TGF-β1-induced growth factors and ECM production in the AECs and 
fibroblasts that are relevant to the progression of lung fibrosis in vitro. We also 
examined the Smad signalling pathway to clarify the mechanism of DOXY in the 




Materials and methods 
Animals 
Nine-week-old male Institute for Cancer Research (ICR)-specific pathogen-free mice 
(Charles River Japan, Inc., Yokohama, Japan) weighing about 35 g were maintained 
under standard conditions with free access to drinking water and pelleted food at the 
Animal Centre of Biomedical Research, Nagasaki University School of Medicine, 
Nagasaki, Japan. The mice were intravenously injected with 10 mg/kg/day of BL 
(Nippon Kayaku, Tokyo, Japan) dissolved (2 mg/ml) in isotonic saline (SA) or with SA 
(5 ml/kg/day) alone for 5 consecutive days [14]. The animals were then orally dosed 
with either 2 mg/kg/day of DOXY (Wako Pure Medical Industries, Ltd., Osaka, Japan) 
in distilled water (0.35 mg/ml) or with distilled water alone as a control once daily, 
starting on the day before or 14 days after being injected i.v. with BL or SA throughout 
the study. The mice were randomly divided into the following groups: SA with distilled 
water (control), BL with distilled water (BL), DOXY 1 day before (pre-DOXY) and 14 
days after (post-DOXY) BL injection. The mice were sacrificed and evaluated at 14, 42, 
and 56 days after the star of BL or SA administration. The Ethics Review Committees 





Histology and fibrosis scores 
At 14, 42 and 56 days after starting BL or SA injections, the mice (n = 3 - 5 per group at 
each time point) were sacrificed by exsanguination under deep anaesthesia (sodium 
pentobarbital, 50 mg/kg, i.p.). The left lungs were then removed via a midline incision, 
fixed in 10% formaldehyde/neutral buffer, and embedded in paraffin and then 4-mm 
sections of embedded tissues were stained with haematoxylin-eosin (HE) and 
immunohistochemically analyzed. The degree of cellular infiltration and fibrosis was 
evaluated from 0 (normal) to 8 (most severe) based on mean Ashcroft scores [15] 
obtained from 25 consecutive microscopic fields that were randomly assessed along the 
pleura of each section. 
 
Immunohistochemistry 
Sections were conventionally analyzed by avidin-biotin-peroxidase histochemical 
staining using the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) for 
TGF-β1, PDGF-A, PDGF-B, CTGF, MMP-2, MMP-9 and collagen type I. Antigen was 
retrieved in 10 mM sodium citrate at pH 6.0 using the steamer protocol for TGF-β1 or 
the standard protocol for PDGF-B, CTGF, MMP-2 and MMP-9. Antigen retrieval for 




protease K using the standard protocol, respectively. Endogenous peroxidase activity 
was quenched by incubation for 20 min in 0.3% H2O2 in absolute methanol. 
Non-specific binding was blocked with 1.5% goat or rabbit serum for 20 min and then 
sections were incubated overnight in rabbit TGF-β1, PDGF-A, CTGF or collagen type I 
antibody (Abcam Inc., Cambridge, MA, USA), rabbit PDGF-B antibody (Gene Tex, 
Irvine, CA, USA) or goat MMP-2 or MMP-9 antibody (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA), respectively. The sections were washed with PBS and further 
processed using the kit according to the manufacturer’s instructions. Areas of interest 
were visualized using 3, 3-diaminobenzidine and H2O2, and then the sections were 
counterstained with Mayer’s haematoxylin. 
 
Measurement of lung hydroxyproline content 
We measured the hydroxyproline content in the right lungs of the mice at 14 and 56 
days after BL or SA injection (n = 3 to 5 in each group) to estimate total collagen 
deposition in the lungs as an indicator of pulmonary fibrosis. Wet lungs were weighed, 
dried, homogenized and hydrolysed in 6 N hydrochloric acid. Hydroxyproline was then 
analyzed in the supernatant at 348 and 450 nm using high-performance liquid 




Cell culture and stimulation 
Human type II alveolar epithelial cells (A549; ATCC, Manassas, VA, USA) and normal 
human lung fibroblasts (Lonza Japan Ltd., Tokyo, Japan) were maintained in low 
glucose-F-12 containing 10% fetal bovine serum (FBS; Life Technologies Corporation, 
Carlsbad, CA, USA) or in fibroblast growth medium (FGM)-2 (Lonza Japan Ltd.), 
respectively, at 37°C in a humidified 5% CO2 atmosphere. Confluent cells were 
incubated in serum-free F-12 medium containing 0.1% bovine serum albumin (BSA) or 
in FGM-2 for 24 h before stimulation with recombinant human TGF-β1 (R&D systems, 
Minneapolis, MN, USA). A549 cells or fibroblasts were incubated with either various 
concentrations of TGF-β1 activated with BSA and HCl or equal amounts of vehicle. 
A549 cells were lysed and harvested 3 h later for reverse transcription (RT) PCR and 
the supernatants were extracted at 24 h for ELISA and MMP activity assays. A549 cells 
were incubated with several concentrations of DOXY from 3 h before stimulation with 
1 ng/ml TGF-β1 until the end of the study. Fibroblasts were stimulated with 5 ng/ml of 







Reverse transcription and real-time PCR 
Primers for PDGF-A, PDGF-B, CTGF, HGF, collagen type I, MMP-2, MMP-9 and 
β-actin mRNA were included in the TaqMan® Gene Expression Assays (Applied 
Biosystems, Foster City, CA, USA). Total RNA was isolated using RNeasy Plus Mini 
kit (Qiagen K.K., Tokyo, Japan) and RT-PCR proceeded using the SuperScript III First 
Strand Synthesis System (Life Technologies Japan Ltd., Tokyo, Japan). The target was 
reverse-transcribed with initial denaturation at 65°C/5 min followed by 40 cycles of 
PCR amplification at 50°C for 50 min, 85°C for 5 min, and 37°C for 20 min using the 
GeneAmp PCR System 9700 (Applied Biosystems). The inner control primer was 
β-actin. The PCR products were analyzed with 7500 system SDS software (Applied 
Biosystems). 
 
ELISA and MMP activity assays 
Concentrations of PDGF-AA, PDGF-AB, PDGF-BB, HGF (R&D systems), and CTGF 
(Antigenix America, Inc., Huntington Station, NY, USA) were analyzed in culture 
media using the appropriate ELISA kit and those of MMP-2 and MMP-9 were 
measured using MMP activity assay systems (GE Healthcare Bio-Science K.K., Tokyo, 




wells of plates pre-coated with primary antibodies. Enzyme-linked antibodies specific to 
each target were added, the plates were washed and chromogenic substrate was added. 
The amount of color generated was measured at 405 nm using a micro-plate reader 
(Bio-Rad Laboratories, Hercules, CA, USA). 
 
Immunocytochemistry 
A549 cells (1  104/well) were seeded onto Lab-TeK® chamber slides (Sigma-Aldrich, 
St. Louis, MO, USA) and maintained until they reached about 80% confluence. The 
cells were stimulated with 1 ng/ml TGF-β1 for 24 h with or without DOXY as described 
above and then examined by immunocytochemistry using the Vectastain Universal Elite 
ABC kit (Vector Laboratories, Burlingame, CA, USA) with goat anti-human collagen 
type I polyclonal antibody (Abcam Inc.) diluted 1:1000 in F-12 medium. 
 
SDS-PAGE and western blotting 
A549 cells were incubated with or without several concentrations of DOXY from 1 h 
before stimulation with 1 ng/ml TGF-β1 until the end of the study. The cells were 
scraped and lysed in cell lysis buffer (Cell Signaling Technology, Danvers, MA) 




after TGF-β1 stimulation. The lysates were centrifuged at 14,000 g for 10 min at 4°C. 
Proteins were separated using 12% reducing SDS-PAGE and transferred to a 
polyvinylidene difluoride membrane (Bio-Rad) in 20% methanol/25 mM Tris–HCl/0.2 
M glycine. Non-specific binding was blocked by incubating the membranes with 5% 
skimmed milk in tris buffer saline with 0.1% Tween 20 for 1 h at room temperature. 
Immunoreactive proteins were detected by incubating the membranes with rabbit 
anti-human Smad2 and Smad3, and phospho-Smad2 and -Smad3 antibodies (Cell 
Signaling Technology) and GAPDH (Santa Cruz Biotechnology, Inc.) diluted at 1:500, 
1:250 and 1:1000, respectively, overnight at 4°C. Subsequently, the membranes were 
incubated for 1 h with anti-rabbit IgG conjugated to HRP (1:10 000), washed and then 
developed using enhanced chemiluminescence reagents (GE Healthcare, 
Buckinghamshire, UK). Western blot images were scanned and analyzed using NIH 
Image J software. Results were expressed as a ratio of band density of phospho-Smad to 
the respective total Smad. 
 
Statistical analysis 
Data were statistically analyzed by an unpaired t-test for pairwise comparisons, and by 




J5.0 (SAS Institute, Inc., Cary, NC). All results are presented as the means ± SD of at 







Effect of DOXY on histological findings in the BL-induced fibrosis model 
A histological evaluation revealed no significant changes in the lungs of the control 
group at 14, 42 and 56 days (Fig. 1A, B, C, respectively), whereas interstitial fibrosis 
was obvious in the lungs of the BL group (Fig. 1D, E, F, respectively) and fibrotic areas 
in the lungs of the pre-DOXY group were reduced (Fig. 1G, H, I, respectively), 
compared with the BL groups. Fibrotic areas were also reduced in the lungs of the 
post-DOXY group at 42 and 56 days (not shown). The mean fibrosis scores in the BL 
group at 14, 42 and 56 days (4.80 ± 1.61, 2.33 ± 0.59, 3.28 ± 0.56, respectively) were 
significantly higher than those in the control group (1.05 ± 0.09, 1.11 ± 0.31, 0.83 ± 
0.18, respectively; Fig. 2). Furthermore, a prior incubation with DOXY significantly 
reduced mean fibrosis scores at 14, 42 and 56 days (3.01 ± 0.35, 1.48 ± 0.34, 1.99 ± 
0.43, respectively; Fig. 2). Post-DOXY also inhibited the score (2.08 ± 0.70; Fig. 2) at 
56 days compared with the BL group. 
 
Effect of DOXY on lung hydroxyproline content in BL-induced fibrosis model 
Figure 3 shows the effect of DOXY on the hydroxyproline content in the right lungs of 




compared with the control group (195.2 ± 31.8 vs. 148.8 ± 11.0 μg/lung) and DOXY 
significantly reduced the level increased by BL (147.0 ± 13.2 μg/lung). The 
hydroxyproline levels induced by BL at 56 days were also significantly elevated and the 
increase was similarly diminished by pre- and post-DOXY. 
 
Effect of DOXY on immunohistochemical expression of fibrotic mediators in a model of 
BL-induced fibrosis 
Figure 4 shows representative immunohistochemically-stained mediators in the model 
of BL-induced fibrosis. Compared with the control group (A, B, C, respectively), the 
immunoreactivity of TGF-β1 (D) was increased mainly in macrophages and AECs, and 
numbers of CTGF (E)-positive cells were obviously increased among enlarged type II 
AECs and fibroblasts in the active fibrotic area in the BL group. The amount of collagen 
type I (F) at ECM was also obviously increased. DOXY reduced the number of cells 
that were positive for TGF-β1 (G), CTGF (H) and collagen type I (I) in the fibrotic area 
in the pre-DOXY group. On the other hand, PDGF-A and PDGF-B was mainly stained 
in macrophages that accumulated in the active fibrotic area of the BL model but not in 
AECs, and DOXY reduced macrophage immunoreactivity (data not shown). 




controls, and MMP-2 immunoreactivity was slightly decreased in the pre-DOXY group 
(data not shown). Macrophages in the BL group were mainly stained for MMP-9, 
whereas MMP-9 immunoreactivity in the pre-DOXY group did not change (data not 
shown). 
 
Effect of DOXY on growth factor mRNA expression and ECM components induced by 
TGF-β1 in AECs 
We assessed the production of TGF-β1-induced profibrotic factors in the alveolar 
epithelial cell line A549 in vitro to determine how DOXY inhibits pulmonary fibrosis in 
the BL model. A preliminary experiment showed that stimulation with TGF-β1 (1 ng/ml 
for 3 h) significantly up-regulated the mRNA expression of PDGF-A, CTGF, collagen 
type I, MMP-2 and MMP-9 and inhibited that of PDGF-B, but did not affect that of 
HGF. Based on these findings, we examined the effect of DOXY on the expression of 
profibrotic factors stimulated with 1 ng/ml of TGF-β1 for 3 h in A549 cells. The mRNA 
expression of PDGF-A, CTGF, collagen type I, MMP-2 and MMP-9 induced by 
TGF-β1 (Fig. 5) was attenuated by DOXY at 15 or 30 μg/ml. Furthermore, DOXY 
up-regulated the expression of PDGF-B that was down-regulated by TGF-β1, but had 




DOXY attenuated the protein production of PDGF-AA, active MMP-2 and collagen 
type I in AEC 
 The secretion of PDGF-AA (Fig. 6A) and active MMP-2 (Fig. 6B) induced by TGF-β1 
was attenuated by DOXY. However, DOXY did not significantly affect PDGF-AB, 
PDGF-BB, HGF and MMP-9 production (data not shown) and CTGF was undetectable 
by ELISA in the supernatant. The production of collagen type I enhanced by 1 ng/ml 
TGF-β1 (Fig. 6C-2) in A549 cells at 24 h compared with control (Fig. 6C-1) was 
attenuated by DOXY (Fig. 6C-3). 
 
Effect of DOXY on TGF-β1-induced Smad signalling pathway 
The phosphorylation of Smad2 and Smad3 was examined in A549 cells at 60 min after 
stimulation with TGF-β1 (1 ng/ml). TGF-β1 induced the phosphorylation of both 
Smad2 and Smad3 without affecting the expression of total Smad2 and Smad3 (Fig. 7A, 
B). DOXY did not affect the TGF-β1-mediated phosphorylation of Smad2 and Smad3. 
 
Effect of TGF-β1 and DOXY on fibroblasts 
We evaluated the effect of DOXY in vitro on fibroblasts, another important target of 




fibroblasts at 48 h after TGF-β1 (5 ng/ml) administration. The mRNA expression of 
MMP-2 and -9, and HGF was not affected by TGF-β1, and neither PDGF-A nor 
PDGF-B were detectable in fibroblasts. Various concentrations of DOXY up to 30 
μg/ml did not affect the CTGF and collagen type I mRNA expression induced by 





The present study demonstrated that DOXY attenuated BL-induced pulmonary 
fibrosis. The production of TGF-1-induced mediators that are considered to play 
important roles in the progression of pulmonary fibrosis was also attenuated by DOXY 
in AECs in vitro. Considering that multiple cycles of epithelial cell damage and 
activation might cause IPF, AECs are considered to play various roles including 
provoking the migration, proliferation and activation of mesenchymal cells along with 
the formation of fibroblastic/myofibroblastic foci and excessive ECM accumulation, 
thus mirroring abnormal wound repair [2]. 
Here, we focused on the effect of DOXY on AECs that release various types of 
growth factors and ECM components that can induce the profibrotic role of fibroblasts 
as described above and conclusively progress pulmonary fibrosis [2]. Among these, 
PDGF, CTGF, HGF and MMPs are considered to play major roles in pulmonary 
fibrosis. The present study showed that DOXY attenuated the TGF-β1-induced mRNA 
expression of PDGF-A, CTGF, MMP-2 and MMP-9, as well as the protein production 
of PGDF-AA and MMP-2 in AECs in vitro. We also showed that DOXY reduced the 
protein production of CTGF in AECs in vivo. 




it has profibrotic activities [16]. The dimeric isoforms PDGF-A and PDGF-B are 
up-regulated in AECs and in bronchoalveolar lavage fluid from the lungs of patients 
with IPF [17] [18]. Although its role is now debatable, the PDGF/PDGF receptor system 
remains a promising target for treating fibrotic diseases [19]. Although we did not 
identify PDGF expression in AECs in our BL model and the reason for the different 
responses of PDGF-A and -B to both TGF-β1 and DOXY remains unknown, our 
findings suggests that DOXY attenuates lung fibrosis by reducing PDGF expression 
from AECs. 
Furthermore, CTGF is considered to act in concert with TGF-β1 downstream and to 
play a significant role in promoting and maintaining fibrogenesis induced by 
proliferating AECs and activated fibroblasts in IPF [20]. Thus, CTGF is also a target in 
IPF and a CTGF-specific antibody has been tested in a clinical trial of patients with IPF 
[1]. Our present findings that DOXY attenuated CTGF production in the BL-model and 
TGF--induced-CTGF expression in AECs suggest that DOXY could attenuate 
pulmonary fibrosis by inhibiting CTGF production from AECs. 
We also showed that DOXY in AECs affected the production of MMP-2 and MMP-9, 
which play roles in cell proliferation, adhesion, migration and differentiation through 




[21]. The gene and protein expression of MMP-2 and MMP-9 is elevated in tissues and 
in bronchoalveolar lavage fluid from patients with IPF [22]. Fujita et al. demonstrated 
that DOXY decreases the production and activity of MMP-9 protein but not the 
expression of MMP-9 mRNA from inflammatory cells in BAL fluid from a model of 
BL-induced pulmonary fibrosis [12]. In addition, the synthetic MMP inhibitor 
batimastat prevents BL-induced pulmonary fibrosis by reducing MMP-2 and MMP-9 
activity [23]. These reports indicate that MMP is a potential therapeutic target of 
pulmonary fibrosis. Although our results in vivo did not uncover a significant 
association between MMP inhibition and pulmonary fibrosis, our in vitro study 
indicates that DOXY reduces pulmonary fibrosis by not only inhibiting MMPs activity 
but also reducing the production of MMP-2 induced by TGF-β1 from AECs. 
The origin of the expanded populations of lung fibroblasts and myofibroblasts in lungs 
with pulmonary fibrosis is of substantial interest. Reports indicate that AECs can serve 
as progenitor cells that can undergo differentiation to fibroblasts/myofibroblasts in 
response to TGF-β with the generation of ECM [3,4]. The process is called epithelial 
mesenchymal transition (EMT), a process by which epithelial cells lose cell-cell 
attachment, polarity and epithelial-specific markers, undergo cytoskeletal remodeling, 




occur in the lungs and contribute to fibrosis in patients with IPF [25]. Mediators such as 
collagen type I, CTGF and MMP-2 that are down-regulated by DOXY in AECs are also 
considered to be markers of EMT [3,26]. These results indicate that DOXY attenuates 
the production of TGF-β-induced mediators by inhibiting EMT. TGF-β-mediated EMT 
is considered to be partly dependent on Smad2 and Smad3 phosphorylation [3,26]. 
Activated Smads mediate transcriptional regulation through other families of 
transcription factors resulting in activation of mesenchymal gene expression including 
MMPs and collagen [27]. DOXY did not reduce TGF-β-induced-Smad phosphorylation 
in the present study. Activation of the Ras-Erk MAP kinase pathway, p38 MAP kinase 
and JNK signaling, as well as Rho GTPase signaling and the PI3 kinase/Akt pathway, 
also contribute to TGF-β-induced EMT [27]. DOXY inhibits TGF-β-induced activation 
of Smad2, JNK, ERK, and p38 MAP kinases in human corneal epithelial cells [28]. 
DOXY also decreases p38 MAP kinase in the TNF-α-, IL-1β- and IFN-γ-treated murine 
lung alveolar epithelial cell line LA4 [6]. Although further studies are required, our 
findings indicated that DOXY attenuates the production of TGF-β-induced mediators in 
alveolar epithelial cells via a non-Smad pathway. 
We also examined the effect of DOXY in lung fibroblasts in vitro. We could not assess 




and MMP-9) in fibroblasts, because TGF-1 stimulation did not affect their expression. 
The RNA expression of CTGF and collagen type I upregulated by TGF-1 stimulation 
was not affected by DOXY. We investigated the effect of DOXY in lung fibroblasts in 
plastic dishes in vitro, and others have reported the influence of collagen type I on 
fibroblast function and the effect of MMP inhibitors such as DOXY [29] [30]. The 
presence of collagen type I in the medium might affect the present results. 
Although one limitation of this study is that only A549 cells and primary human lung 
fibroblasts were investigated, the inhibitory effect of DOXY on pulmonary fibrosis 
might be partly explained as reduced production of profibrotic factors from AECs but 
not from lung fibroblasts. 
We used TGF-1 to stimulate AECs and lung fibroblasts in vitro. TGF-1 plays the 
most pivotal role in the development and progress of fibrosis. The present study showed 
that DOXY reduced TGF-1 expression in a model of pulmonary fibrosis induced by 
BL. Although the precise mechanism of the reduced TGF-1 expression in BL-induced 
pulmonary fibrosis remains unknown, our results in vitro and in vivo suggest that 
DOXY attenuates pulmonary fibrosis by reducing both TGF-1 production and the 
TGF-1-induced fibrotic response. Additionally, DOXY attenuated fibrosis in both pre- 




fibrosis is attenuated by earlier, but not by later, DOXY administration, which is 
somewhat controversial. Although the two studies are similar, the species of mouse and 
period of BL administration differ. The most obvious difference is in the administration 
routes of BL, which was intratracheally in the previous report and intravenously in the 
present study. Intratracheal BL reportedly induces lung fibrosis by day 14, whereas 
intravenous administration induces fibrosis more slowly [31]. These factors might 
explain the different results. DOXY inhibits inflammation not only during the earlier 
phase, but also fibrosis at the later phase of pulmonary fibrosis. 
Advances in elucidating disease pathogenesis and identifying new targets for treating 
IPF have recently led to several clinical trials of many agents. However, none has 
unequivocally caused a survival benefit. Consequently, the search for safe and effective 
agents for treating IPF continues [32]. The therapeutic mechanisms of DOXY remain 
unknown, and evidence of its effectiveness in patients with IPF is inadequate. On the 
other hand, prolonged therapy with DOXY is well tolerated for several months under 
various conditions [13]. This could be favorable for treating IPF. Our data support the 
notion that DOXY could become a therapeutic option for the treatment of IPF. 
In conclusion, DOXY appears to attenuate pulmonary fibrosis through the inhibition 
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Figure legends  
 
Fig. 1. Representative photographs of lungs from each group at various times (H&E 
stain). 
At days 14, 42 and 56, interstitial fibrosis is evident in lungs from BL group (D, E, F, 
respectively) compared with control lungs (A, B, C, respectively) and fibrotic areas are 
obviously reduced in lungs of pre-DOXY group (G, H, I, respectively), relative to those 





Fig. 2. Effects of DOXY on fibrosis scores of BL-induced fibrosis model at various 
times. 
Pre-DOXY incubation reduced Ashcroft scores of BL-induced fibrosis model at days 14, 
42 and 56 compared with the BL group. Post-DOXY incubation also reduced this score 
at 56 days compared with the BL group. 
   Control,    BL,    pre-DOXY,    post-DOXY. The results are expressed as 






Fig. 3. Effects of DOXY on hydroxyproline content in BL-induced fibrosis model at 
various times. 
Incubation with DOXY at day 14 significantly reduced hydroxyproline levels relative to 
corresponding values of BL-treated group. Similar tendency at day 56 did not reach 
significance. 
   Control ,     BL ,     pre-DOXY,    post-DOXY. The results are expressed as 
mean ± SD of data from 3 to 5 animals. *p < 0.05 compared with other groups at 





Fig. 4. Immunohistochemical evaluation of control, BL and pre-DOXY groups at day 
56. Type-II AECs and macrophages are positive for TGF-β1 (A) and type-II AECs are 
positive for CTGF (B). Collagen type I is essentially undetectable (C) in control lung. 
Proliferative, TGF-β1- (D) and CTGF- (E) positive cells in active fibrotic area and 
collagen type I positive ECM (F) are increased in lungs from BL group. Numbers of 
TGF-β1- (G) and CTGF H)-positive cells as well as collagen type I production (I) are 





Fig. 5. Effects of DOXY on mRNA expression of growth factors, collagen type I and 
MMPs induced by TGF-β1 in A549 cells. 
DOXY attenuated TGF-β1-induced mRNA expression of PDGF-A, CTGF, collagen 
type I, MMP-2 and MMP-9, but recovered PDGF-B mRNA expression inhibited by 
TGF-β1. Data are presented as means ± SD. *p < 0.05 compared with expression after 3 




Fig. 6. Effects of DOXY on production of PDGF-AA, collagen type I and active 
MMP-2 induced by TGF-β1 in A549 cells. 
ELISA and MMP activity assays show that DOXY attenuated production of PDGF-AA 
(A) and active MMP-2 (B) induced by TGF-β1 in supernatant. DOXY attenuated 
production of collagen type I enhanced by 1 ng/ml TGF-β1 (Fig. 6C-2) in A549 cells at 
24 h compared with control (C-1, C-3) (immunocytochemical staining). Data are shown 





Fig. 7. Effects of DOXY on TGF-β1-induced Smad signalling pathway. 
TGF-β1 induced expression of phospho-Smad2 (A) and phospho-Smad3 (B) but did not 
affect total Smad2 and Smad3 values. DOXY did not affect Smad2 and Smad3 
phosphorylation. Data are presented as means ± SD. *p < 0.05. 
 
